BNP Paribas Asset Management
NKTR icon

BNP Paribas Asset Management’s Nektar Therapeutics NKTR Stock Holding History

BNP Paribas Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.6K Buy
397
+219
+123% +$12.5K ﹤0.01% 1917
2025
Q4 		$8K Buy
+178
New +$9.96K ﹤0.01% 2222
2019
Q3 		– Sell
-397
Closed -$212K – 870
2019
Q2 		$212K Buy
+397
New +$199K ﹤0.01% 879
2019
Q1 		– Sell
-678
Closed -$342K – 932
2018
Q4 		$342K Hold
678
– – ﹤0.01% 835
2018
Q3 		$620K Sell
678
-575
-46% -$491K ﹤0.01% 768
2018
Q2 		$918K Buy
+1,253
New +$1.44M 0.01% 753

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BNP Paribas Asset Management's NKTR Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Nektar Therapeutics (NKTR) stake by 123% in Q1 2026, buying an estimated $12.5K and bringing the position to 397 shares worth $28.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

BNP Paribas Asset Management first reported a position in NKTR in Q2 2018 and has held it in 6 quarters since. The position peaked at $918K in Q2 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • BNP Paribas Asset Management held 397 shares of Nektar Therapeutics worth $28.6K as of Q1 2026.
  • BNP Paribas Asset Management bought 219 Nektar Therapeutics shares in Q1 2026, an estimated $12.5K.
  • Nektar Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1917 holding.
  • BNP Paribas Asset Management first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • BNP Paribas Asset Management's Nektar Therapeutics position peaked at $918K in Q2 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.